Lundbeck: This is our focus for 2014 and 2015
The new drugs segment from Lundbeck is likely to reach a turnover of USD 544m this year, says CFO Anders Götzsche, and the focus in coming years will be on increasing that figure with the help of three newcomers.
by Stefan Singh Kailay
There was decline pretty much across the board for Lundbeck in Q3, but the company still performed better than expected, and, looking at the first nine months of the year, there was growth – which is also what CFO Anders Götzsche focuses on.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
VP: Lundbeck first with new Alzheimer’s drug
For abonnenter
Doctors represent hurdle for Lundbeck once again
For abonnenter
Here are Lundbeck’s best-performing drugs
For abonnenter
